A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

This trial is testing whether empagliflozin — a drug originally used for type 2 diabetes and heart failure — can also benefit patients with pulmonary arterial hypertension (PAH), a serious condition where high pressure in the blood vessels of the lungs strains the heart. Patients will take empagliflozin on top of their existing PAH medications. **You may be eligible if...** - You are 18 or older with a confirmed PAH diagnosis (verified by right heart catheterization) - Your PAH is from an idiopathic, hereditary, drug-induced cause, or is associated with connective tissue disease or certain congenital heart conditions - You are on stable PAH medications (endothelin receptor antagonists, PDE5 inhibitors, or sGC stimulators) - You can walk at least 150 meters in 6 minutes **You may NOT be eligible if...** - You have diabetes - Your PAH is caused by a blood clot in the lungs (chronic thromboembolic disease) - You have severe liver disease, significant kidney dysfunction (creatinine > 2.5 mg/dL), or low hemoglobin - You are pregnant or breastfeeding - You have already received IV or SC prostacyclin medications Talk to your doctor to see if this trial is right for you.